Symbiobe Inc. secured 800 million yen in Series A funding to enhance its innovative technology aimed at converting atmospheric CO2 into usable resources.

Information on the Target

We are pleased to announce our investment in Symbiobe Inc., a company focused on utilizing marine red photosynthetic bacteria to aim for the "resource conversion of air." Symbiobe is pioneering innovative solutions that leverage microbial processes to capture and convert atmospheric CO2 into usable resources, addressing significant environmental challenges.

The company recently completed a Series A funding round, successfully raising 800 million yen. This capital infusion will enhance Symbiobe's research and development efforts, supporting their ambitious goals in sustainability and resource management.

Industry Overview in Japan

Japan's biotechnology sector has shown remarkable growth, driven by advancements in research and development, technological innovations, and increasing investments in sus